Opya, Inc.

Opya, Inc. is a specialized provider of Applied Behavior Analysis (ABA) therapy services for children with autism, focusing on personalized treatment to enhance social skills and developmental milestones. Founded in 2015 and headquartered in San Mateo, US, Opya, Inc. offers individualized ABA therapy.

The company has successfully closed 2 funding deals, with the most recent being a Series A round in August 2021, raising USD 3. 000 mn led by BIP Ventures. The company was founded by Jonathan Wright, and Alden Romney currently serves as CEO. Opya specializes in delivering individualized Applied Behavior Analysis (ABA) therapy for children diagnosed with autism, primarily targeting ages 18 months to 6 years.

Core offerings include one-on-one ABA therapy sessions and collaborative engagements with parents and caregivers, enhancing treatment effectiveness. Their approach integrates complementary therapies, such as speech and occupational therapy, ensuring comprehensive care. Services are available across Northern and Southern California, catering to families seeking early intervention solutions for autism. Opya's revenue is derived from direct transactions with families and caregivers seeking autism therapy.

The company operates on a business-to-consumer model, where clients engage for personalized therapy programs, including ABA sessions and supplementary services. Revenue comes from service fees and potential insurance reimbursements, supported by partnerships with major commercial payors and Medi-Cal plans. Their structured pricing reflects the collaborative nature of care, focusing on ongoing client engagement to ensure a sustainable revenue model for specialized autism care. In August 2021, Opya, Inc.

raised USD 3. 000 mn in Series A funding, led by Panoramic Ventures, to enhance its clinical care and accelerate product innovation. The funding will be utilized to scale their operations and add leadership talent. Opya plans to expand its services into new regions across California, with further geographical expansion to be determined based on market evaluations.

The aim is to ensure high-quality clinical standards while developing new treatment solutions tailored for children with autism.